

3 December 2025

**Fevera plc**

("Fevera", the "Group" or the "Company")

**Fevera enters Brazil with acquisition of Domino Industria E Comercio LTDA**

*Initial move into strategically significant Brazilian market, establishing a southern hemisphere footprint and supporting delivery of the Group's strategy*

Fevera plc (LSE: FVA), an international specialist in livestock supplements, is pleased to announce that it has entered into an agreement for the acquisition of Domino Industria E Comercio LTDA, trading as Macal ('Macal') in the strategically significant Brazilian market (the "Acquisition").

The initial consideration will be £5.0m, with a further £0.8m-£1.9m of deferred consideration payable in March 2028, subject to business performance, with both elements of the consideration being funded from the Group's existing resources. Macal is cash generative and is expected to be earnings accretive to the Group in the first full year of ownership, having delivered EBITDA of approximately £0.7m (unaudited) in the last 12 months. The Group expects to acquire Macal on a cash free, debt free basis with normalised working capital on completion.

The Acquisition represents a compelling strategic fit with Fevera's ambition to target medium-term access to Brazil's considerable population of more than 200 million cattle. This provides a highly complementary addition to the Group's existing northern hemisphere markets which comprise approximately 110 million cattle. The Acquisition comes after a period of extensive market, product and targets evaluation conducted with local specialist resource.

The Acquisition is expected to close within 6-8 weeks, on completion of certain deliverables.

Macal is a leading provider of minerals and supplements, offering a wide range of products across several branded lines for cattle, sheep and horses. All products are manufactured at its own site in Campo Grande, Mato Grosso do Sul, Brazil, and sold through its regional distribution and commercial network, supported by strong brands and experienced management and commercial teams. Currently, Macal's sales are focused almost entirely within the state of Mato Grosso do Sul, which has 19 million head of cattle and the second-highest cattle density in Brazil. The business is strategically positioned next to Mato Grosso, Goiás and São Paulo states, which together account for a further 67 million cattle, representing significant market potential. Macal's product range and existing sales capability is highly synergistic with Fevera's core low moisture block product line which will be introduced in Brazil in due course.

Macal's management team will remain with the business, working closely with local Fevera country management to extend distribution and to introduce Fevera's specialist, proven products, adapted for the Brazilian market in due course.

**Joshua Hoopes, Chief Executive of Fevera commented:**

"I'm delighted to announce our first acquisition under our refreshed strategy as an international specialist agriculture manufacturer. As we target expansion in southern hemisphere markets, Brazil represents a natural entry point, given its substantial cattle population and long-term growth potential."

"Macal is a strong strategic fit for Fevera, and I look forward to partnering with its experienced team and leveraging its established commercial network to expand distribution and introduce our specialist products to the Brazilian market."

**For further information, please contact:**

**Enquiries**

**Fevera plc**

+44 (0) 1228 554 600

Joshua Hoopes, Chief Executive Officer

Gavin Manson, Chief Financial Officer

**About Fevara plc:**

Fevara is an international specialist in livestock supplements.

Fevara's purpose is to empower farmers in extensive grazing systems with research-proven products that boost profitability, improve resource efficiency and support sustainable agriculture. The Group develops, manufactures and markets research-proven supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses, sold under recognised and trusted brands, including Crystalyx®, Horslic®, Horslyx®, Scotmin Nutrition®, SmartLic® and Tracesure® Advanced.

Headquartered in Carlisle, Cumbria, in the UK, Fevara has four manufacturing sites in the UK and the US, with three operational joint ventures in Germany and the US. It serves customers in more than 20 countries through its expansive international distribution and support network.

Fevara has been listed on the London Stock Exchange since 1972.

For more information, visit: [www.fevara.com](http://www.fevara.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQKZMGZFZRGKZZ